Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis eukaryotic-prokaryotic dual expressing OVA enhances antitumor efficacy by both direct and cross-presentation
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115263 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Tingting Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, …. Hauptthemen laut MEDLINE: Dendritic Cells, Lactococcus lactis, Cancer Vaccines, Ovalbumin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Probiotic Lactococcus lactis (L.L) can act as an antigen delivery carrier to cross-present (XPT) exogenous antigens in dendritic cells (DCs). To optimize antigen XPT in a DC-based vaccine for improved antitumor efficacy, we produced recombinant L.L strains expressing the model antigen OVA via distinct methods: prokaryotic expression alone, eukaryotic expression alone, or dual prokaryotic-eukaryotic expression (designated pOVA-L.L, eOVA-L.L, and dOVA-L.L, respectively). These strains were used to deliver antigens into DCs. Although all three recombinant OVA-L.L strains significantly enhanced DCs' ability to promote OT-I cell proliferation (with dOVA-L.L-treated DCs (dOVA-L.L-DCs) showing the strongest effect), only dOVA-L.L-DCs demonstrated significantly more potent antitumor efficacy in the B16-OVA tumor mouse model, consistent with the in vitro data. Further investigation into the mechanisms underlying the enhanced antigen XPT and anti-tumor efficacy of dOVA-L.L-DCs revealed that pOVA-L.L and dOVA-L.L resided both inside and outside lysosomes, whereas eOVA-L.L was located exclusively outside lysosomes. Consequently, dOVA-L.L-DCs could XPT higher amounts of MHC I-OVA peptide complex on their surface. Furthermore, these DCs could also directly present lysosome-derived OVA peptide-MHC II complexes to stimulate antigen-specific CD4+ T cell responses in vivo. Collectively, these mechanisms induced more persistent cellular immune responses than either of the other two recombinant L.L-DCs. In conclusion, we developed an enhanced antigen delivery system using probiotic food-grade bacteria. This system promotes the prolonged expression of exogenous antigens and significantly enhances the XPT capacity of DC vaccines for tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China; Xinjiang Academy of Agricultural Sciences, Urumqi 830091, China.
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China. Electronic address: liyijie@xju.edu.cn.
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China. Electronic address: yuekang.xu@hotmail.com.
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China. Electronic address: ljyxju@xju.edu.cn.
Zitieren
APA
Zhang, T., Huang, S., Liu, P., Su, X., Zou, J., Wu, Y., Li, Y., Xu, Y., & Li, J. (2025). Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis eukaryotic-prokaryotic dual expressing OVA enhances antitumor efficacy by both direct and cross-presentation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115263
Vancouver
Zhang T, Huang S, Liu P, Su X, Zou J, Wu Y, et al. Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis eukaryotic-prokaryotic dual expressing OVA enhances antitumor efficacy by both direct and cross-presentation. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115263
BibTeX
@article{Zhang2025,
author = {Zhang, Tingting and Huang, Shuai and Liu, Peng and Su, Xiaoqiu and Zou, Jiahe and Wu, Yulin and Li, Yijie and Xu, Yuekang and Li, Jinyao},
title = {Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis eukaryotic-prokaryotic dual expressing OVA enhances antitumor efficacy by both direct and cross-presentation},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115263}
}
EUVIMED